Shares of Gilead Sciences, Inc. (GILD) were in the spotlight on Friday morning after the company reportedly said that it ...

U.S. President Donald Trump heads to Pittsburgh, Pennsylvania on Friday to headline a rally to celebrate Nippon Steel's ...

Lenacapavir works to both treat and prevent HIV, making it a promising drug should it be approved by the FDA later this month.

Gilead's twice-yearly HIV injection faces headwinds from US aid pullback. Thank you for reading Nation.Africa Show plans Gilead Sciences says it still plans to supply its twice-yearly injection for ...

Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...

The Trump administration has moved to end funding for a broad swath of HIV vaccine research, saying current approaches are ...

Gilead Sciences is paying $10 million for sole ownership of arenavirus immunotherapies for hepatitis B (HBV) and HIV ...

At current levels, we recommend prospective investors to opt for GSK as compared to GILD on the back of a strong and wide ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

Gilead Sciences says it still plans to supply its twice-yearly injection for preventing HIV infection in low-income countries if it wins U.S. approval despite funding uncertainty over the Trump ...